Cargando…

Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy

Introduction: Therapy options for patients with oligoprogressive malignant pleural mesothelioma (MPM) are limited. Stereotactic Body Radiotherapy (SBRT) may be a promising therapeutic option, as it delivers a localized ablative dose of radiation and therefore balances efficacy and treatment related...

Descripción completa

Detalles Bibliográficos
Autores principales: Schröder, Christina, Opitz, Isabelle, Guckenberger, Matthias, Stahel, Rolf, Weder, Walter, Förster, Robert, Andratschke, Nicolaus, Lauk, Olivia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775182/
https://www.ncbi.nlm.nih.gov/pubmed/31616640
http://dx.doi.org/10.3389/fonc.2019.00961
_version_ 1783456184618975232
author Schröder, Christina
Opitz, Isabelle
Guckenberger, Matthias
Stahel, Rolf
Weder, Walter
Förster, Robert
Andratschke, Nicolaus
Lauk, Olivia
author_facet Schröder, Christina
Opitz, Isabelle
Guckenberger, Matthias
Stahel, Rolf
Weder, Walter
Förster, Robert
Andratschke, Nicolaus
Lauk, Olivia
author_sort Schröder, Christina
collection PubMed
description Introduction: Therapy options for patients with oligoprogressive malignant pleural mesothelioma (MPM) are limited. Stereotactic Body Radiotherapy (SBRT) may be a promising therapeutic option, as it delivers a localized ablative dose of radiation and therefore balances efficacy and treatment related toxicities. The intent of this retrospective analysis was to evaluate the feasibility of SBRT for limited pleural recurrences. Methods and Materials: This retrospective single-institution study is based on the 21 consecutive patients treated with hypofractionated radiotherapy for oligoprogressive MPM. Clinical and radiological data was collected at regular follow-up visits including toxicity, local control and survival. Results: At primary diagnosis, 57% of the patients presented with stage III disease. Initial treatment of MPM consisted of induction chemotherapy (n = 12) prior to a macroscopic complete resection (n = 18). Three patients received additional intracavitary chemotherapy and another three patients were treated with chemotherapy alone without another treatment at the time of first diagnosis. A total of 50 lesions in recurrent MPM were treated with SBRT. The median number of radiotherapy fractions was 5 (range 3–20) with a median dose per fraction of 5 Gy (range 2.5–12.5 Gy). The median total treatment dose was 30 Gy (20–50 Gy) with a median prescription isodose line (IDL) of 65% (65–100%). Median follow-up of all patients from diagnosis was 28 months (range 7–152 months). Analyzing all lesions separately, the 12-months-local control from SBRT was 73.5%. The median progression free survival (PFS) after SBRT was 6 months (range 0–21 months) and the median OS from first first SBRT was 29 months (range 0–61 months). Only one patients experienced above Grade 3 toxicities. Conclusion: This analysis demonstrates the feasibility of a SBRT approach for oligorecurrent MPM. SBRT was well-tolerated even after multiple repetitions and local control was high with a promising median OS.
format Online
Article
Text
id pubmed-6775182
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-67751822019-10-15 Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy Schröder, Christina Opitz, Isabelle Guckenberger, Matthias Stahel, Rolf Weder, Walter Förster, Robert Andratschke, Nicolaus Lauk, Olivia Front Oncol Oncology Introduction: Therapy options for patients with oligoprogressive malignant pleural mesothelioma (MPM) are limited. Stereotactic Body Radiotherapy (SBRT) may be a promising therapeutic option, as it delivers a localized ablative dose of radiation and therefore balances efficacy and treatment related toxicities. The intent of this retrospective analysis was to evaluate the feasibility of SBRT for limited pleural recurrences. Methods and Materials: This retrospective single-institution study is based on the 21 consecutive patients treated with hypofractionated radiotherapy for oligoprogressive MPM. Clinical and radiological data was collected at regular follow-up visits including toxicity, local control and survival. Results: At primary diagnosis, 57% of the patients presented with stage III disease. Initial treatment of MPM consisted of induction chemotherapy (n = 12) prior to a macroscopic complete resection (n = 18). Three patients received additional intracavitary chemotherapy and another three patients were treated with chemotherapy alone without another treatment at the time of first diagnosis. A total of 50 lesions in recurrent MPM were treated with SBRT. The median number of radiotherapy fractions was 5 (range 3–20) with a median dose per fraction of 5 Gy (range 2.5–12.5 Gy). The median total treatment dose was 30 Gy (20–50 Gy) with a median prescription isodose line (IDL) of 65% (65–100%). Median follow-up of all patients from diagnosis was 28 months (range 7–152 months). Analyzing all lesions separately, the 12-months-local control from SBRT was 73.5%. The median progression free survival (PFS) after SBRT was 6 months (range 0–21 months) and the median OS from first first SBRT was 29 months (range 0–61 months). Only one patients experienced above Grade 3 toxicities. Conclusion: This analysis demonstrates the feasibility of a SBRT approach for oligorecurrent MPM. SBRT was well-tolerated even after multiple repetitions and local control was high with a promising median OS. Frontiers Media S.A. 2019-09-26 /pmc/articles/PMC6775182/ /pubmed/31616640 http://dx.doi.org/10.3389/fonc.2019.00961 Text en Copyright © 2019 Schröder, Opitz, Guckenberger, Stahel, Weder, Förster, Andratschke and Lauk. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Schröder, Christina
Opitz, Isabelle
Guckenberger, Matthias
Stahel, Rolf
Weder, Walter
Förster, Robert
Andratschke, Nicolaus
Lauk, Olivia
Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy
title Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy
title_full Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy
title_fullStr Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy
title_full_unstemmed Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy
title_short Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy
title_sort stereotactic body radiation therapy (sbrt) as salvage therapy for oligorecurrent pleural mesothelioma after multi-modality therapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775182/
https://www.ncbi.nlm.nih.gov/pubmed/31616640
http://dx.doi.org/10.3389/fonc.2019.00961
work_keys_str_mv AT schroderchristina stereotacticbodyradiationtherapysbrtassalvagetherapyforoligorecurrentpleuralmesotheliomaaftermultimodalitytherapy
AT opitzisabelle stereotacticbodyradiationtherapysbrtassalvagetherapyforoligorecurrentpleuralmesotheliomaaftermultimodalitytherapy
AT guckenbergermatthias stereotacticbodyradiationtherapysbrtassalvagetherapyforoligorecurrentpleuralmesotheliomaaftermultimodalitytherapy
AT stahelrolf stereotacticbodyradiationtherapysbrtassalvagetherapyforoligorecurrentpleuralmesotheliomaaftermultimodalitytherapy
AT wederwalter stereotacticbodyradiationtherapysbrtassalvagetherapyforoligorecurrentpleuralmesotheliomaaftermultimodalitytherapy
AT forsterrobert stereotacticbodyradiationtherapysbrtassalvagetherapyforoligorecurrentpleuralmesotheliomaaftermultimodalitytherapy
AT andratschkenicolaus stereotacticbodyradiationtherapysbrtassalvagetherapyforoligorecurrentpleuralmesotheliomaaftermultimodalitytherapy
AT laukolivia stereotacticbodyradiationtherapysbrtassalvagetherapyforoligorecurrentpleuralmesotheliomaaftermultimodalitytherapy